Investigational drug · Phase 3
VSA012
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Paroxysmal Nocturnal Hemoglobinuria, PNH.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "VSA012"
First trial start
2026
Oct 29, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VSA012", any sponsor or status.
Conditions studied
As listed on its trial records.
- Paroxysmal Nocturnal Hemoglobinuria, PNH
Approved drugs for the same conditions: Paroxysmal nocturnal hemoglobinuria
Largest trials
Live from ClinicalTrials.gov: studies naming "VSA012" as an intervention, largest first.
- A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor TherapyPivotal-lookingNot yet recruiting
Bisirna Therapeutics (Suzhou) Co., Ltd.Industry
NCT07816237 · 70 participants (planned) · Start Oct 29, 2026 · Primary completion Sep 30, 2027
Drug: VSA012; Eculizumab (Soliris®) · For: Paroxysmal Nocturnal Hemoglobinuria, PNH
Sites: Beijing, China; Jilin City, China; Quanzhou, China · 14 sites in all
- Phase Ib Clinical Study to Evaluate the Safety and Tolerability of VSA012 Injection in Paroxysmal Nocturnal HemoglobinuriaActive, not recruiting
Bisirna Therapeutics Pte. Ltd.Industry
NCT06848296 · 50 participants · Start Apr 15, 2025 · Primary completion Feb 28, 2027
Drug: VSA012 · For: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Sites: Beijing, China; Hangzhou, China
- A Phase I Clinical Study of VSA012 in Healthy VolunteersActive, not recruiting
Bisirna Therapeutics (Suzhou) Co., Ltd.Industry
NCT06766929 · 40 participants · Start Jan 20, 2025 · Primary completion Aug 2026
Drug: VSA012; Placebo · For: Healthy Volunteers
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.